NextPlat (NASDAQ:NXPL) Posts Earnings Results

NextPlat (NASDAQ:NXPL) posted its earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, Zacks reports. The business had revenue of $9.86 million for the quarter. NextPlat had a negative return on equity of 55.07% and a negative net margin of 23.14%.

Here are the key takeaways from NextPlat’s conference call:

• NextPlat said its turnaround is largely complete, with Q1 showing record-level gross margins, lower operating expenses, and a clear path to improving profitability in the second half of 2026.
• The healthcare segment posted a major improvement, with gross margin rising to 39% from about 20% a year ago and the segment generating positive operating income for the quarter.
• The company secured five new 340B pharmacy service agreements in the quarter, a record, and expects those customers to begin contributing to revenue in the third quarter after onboarding.
• Management highlighted new growth initiatives, including a nationwide fulfillment partnership and a planned e-commerce healthcare site that will sell prescription drugs, GLP-1 products, and OTC items, expected to launch before the end of Q2.
• Quarterly revenue declined year over year to about $10 million, though the company said the mix is shifting toward higher-margin contract and fulfillment revenue, while e-commerce remained steady at about $3.2 million.

NextPlat Stock Performance

NXPL traded down $0.20 during trading on Friday, hitting $6.06. The stock had a trading volume of 2,349 shares, compared to its average volume of 11,935. The company has a 50 day moving average price of $5.44 and a 200-day moving average price of $6.07. The firm has a market cap of $16.41 million, a price-to-earnings ratio of -1.40 and a beta of 1.91. NextPlat has a one year low of $3.38 and a one year high of $11.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.65 and a quick ratio of 2.27.

Analysts Set New Price Targets

Separately, Weiss Ratings raised NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of NextPlat

An institutional investor recently bought a new position in NextPlat stock. Citadel Advisors LLC purchased a new stake in NextPlat Corp. (NASDAQ:NXPL) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.19% of NextPlat at the end of the most recent reporting period. Institutional investors own 1.30% of the company’s stock.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.